Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Clinuvel Pharmaceuticals (CLVLF) vs. Competitors

42 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
CLVLFClinuvel Pharmaceuticals $4.91$250.51M10.85-31.78%Moderate BuyUnlock the CLVLF analyst price target with TipRanks PremiumCLVLFUnlock the CLVLF top-analyst price target with TipRanks Premium
AU:ACRAcrux AUD 0.01AUD 5.82M-6.43-33.33%―Unlock the AU:ACR analyst price target with TipRanks PremiumCLVLF vs AU:ACRUnlock the AU:ACR top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.42AUD 200.41M-24.271.47%―Unlock the AU:SPL analyst price target with TipRanks PremiumCLVLF vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.73AUD 1.70B-29.1935.93%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumCLVLF vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 27.63M-0.31-92.31%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumCLVLF vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:BIOBiome Australia LtdAUD 0.36AUD 83.31M22.36-17.24%Moderate BuyUnlock the AU:BIO analyst price target with TipRanks PremiumCLVLF vs AU:BIOUnlock the AU:BIO top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
CLVLFClinuvel Pharmaceuticals 4.91-2.17-30.62%
AU:ACRAcrux 0.01-0.01-37.50%
AU:SPLStarpharma Holdings Limited0.410.011.47%
AU:PYCPYC Therapeutics Limited1.730.5040.24%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.00%
AU:BIOBiome Australia Ltd0.36-0.07-16.28%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts